Health

Foresight Diagnostics to demonstrate utility of PhasED-Seq technology at ICML meeting – News-Medical.Net

Foresight Diagnostics, the emerging leader in blood-based lymphoma disease monitoring, announced today that clinical performance…

Published

4 years ago

June 18, 2021

Noosa Online News Publisher

Foresight Diagnostics, the emerging leader in blood-based lymphoma disease monitoring, announced today that clinical performance of its minimal residual disease (MRD) detection platform in diffuse large B-cell lymphoma (DLBCL) will be presented at the 16th…

Click here to view the original article.

Related Topics:Australia News-Medical.Net

Up Next

Alarming COVID study indicates long-term loss of gray matter and other brain tissue – News-Medical.Net

Don't Miss

Study finds that immune system protein may defend against deadly intestinal disease in babies – EdexLive

Noosa News19 hours ago

Reubhan Ralph identified as man behind terrifying childcare centre incident in Peregian Springs on the Sunshine Coast

General18 hours ago

Police say new leads being pursued after baby’s body found in Alexander Heights stormwater drain

Noosa News21 hours ago

Women’s Softball World Cup 2027 Redcliffe Brisbane

General21 hours ago

Man dies at shopping centre car park at Charlestown following reports of assault

Noosa Online News

Foresight Diagnostics to demonstrate utility of PhasED-Seq technology at ICML meeting – News-Medical.Net

Trending